Thalassemia, a debilitating genetic blood disorder, represents a significant public health challenge in India, often referred to as a silent epidemic due to its high prevalence and the continuous, life-long nature of its treatment. The country grapples with the highest burden of this disease globally, with an estimated 150,000 individuals affected and approximately 10,000 to 15,000 children born annually with the severe form, Thalassemia Major.

This immense patient load necessitates a comprehensive, scaled-up healthcare response, spanning advanced diagnostics, regular blood transfusions, and critical drug therapies. The sheer volume of affected individuals and carriers—estimated to be in the tens of millions—is the primary engine driving the substantial growth of the **India Thalassemia Market** as healthcare providers and manufacturers strive to meet this urgent clinical demand.